Skip to main content
. 2016 Jun 3;7(26):40657–40673. doi: 10.18632/oncotarget.9813

Figure 4. eIF4E contributes to miR-558-facilitated HIF-2α expression in NB cells.

Figure 4

A. Co-IP assay showing the binding of eIF4EBP1 to AGO2 in NB cells transfected with empty vector (mock), miR-558 precursor, anti-NC (100 nmol/L) or anti-miR-558 (100 nmol/L) inhibitors. B. and C. RNA pull-down and RIP assays indicating the binding of eIF4E to HIF-2α 5′-UTR in NB cells transfected with mock, miR-558 precursor, anti-NC (100 nmol/L) or anti-miR-558 (100 nmol/L) inhibitors. D. western blot assay showing the expression of eIF4E and HIF-2α in NB cells stably transfected with mock or miR-558 precursor, and those co-transfected with sh-Scb or sh-eIF4E. E. dual-luciferase assay indicating the activity of HIF-2α 5′-UTR luciferase reporter in SH-SY5Y and SK-N-SH cells stably transfected with mock or miR-558 precursor, and those co-transfected with sh-Scb or sh-eIF4E. * P<0.01 vs. anti-NC, mock, or mock+sh-Scb.